Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020

Autor: Sheri D. Schully, James Michael Cherry, Hoda Anton-Culver, Keri N. Althoff, Adrienne S. Roman, Isaac P. Thomsen, Carolyn Williams, Mine S. Cicek, Joshua C. Denny, Kelly A. Gebo, Ligia A. Pinto, David Goldstein, Bradley A. Malin, David Jeffrey Schlueter, Lucila Ohno-Machado, Elizabeth W. Karlson, Aymone Kouame, Fiona Havers, Andrea H. Ramirez, Douglas R. Lowy, Stephen N. Thibodeau, Norman E. Sharpless

Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 74, iss 4

Background With limited severe acute respiratory syndrome coronavirus (SARS-CoV-2) testing capacity in the United States at the start of the epidemic (January–March 2020), testing was focused on symptomatic patients with a travel history throughout

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b2c6be1637994b104b998fe41169f4
https://pubmed.ncbi.nlm.nih.gov/34420046